Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial

被引：0
|
作者：
Murphy, Sabina A.
Pedersen, Terje R.
Gaciong, Zbigniew A.
Ceska, Richard
Ezhov, Marat V.
Connolly, Derek
Kraydashenko, Oleg
Jukema, J. Wouter
Toth, Kalman
Tikkanen, Matti J.
Im, Kyungah
Wiviott, Stephen D.
Kurtz, Christopher
Honarpour, Narimon
Giugliano, Robert P.
Keech, Anthony C.
Sever, Peter S.
Sabatine, Marc S.
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
LDLPCSK9;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15100
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PCSK9 inhibitors in the prevention of cardiovascular disease
    James Latimer
    Jonathan A. Batty
    R. Dermot G. Neely
    Vijay Kunadian
    Journal of Thrombosis and Thrombolysis, 2016, 42 : 405 - 419
  • [22] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
    Rosenson, Robert S.
    Jacobson, Terry A.
    Preiss, David
    Djedjos, C. Stephen
    Dent, Ricardo
    Bridges, Ian
    Miller, Michael
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (03) : 305 - 313
  • [23] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
    Robert S. Rosenson
    Terry A. Jacobson
    David Preiss
    C. Stephen Djedjos
    Ricardo Dent
    Ian Bridges
    Michael Miller
    Cardiovascular Drugs and Therapy, 2016, 30 : 305 - 313
  • [24] Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
    Kasichayanula, Sreeneeranj
    Grover, Anita
    Emery, Maurice G.
    Gibbs, Megan A.
    Somaratne, Ransi
    Wasserman, Scott M.
    Gibbs, John P.
    CLINICAL PHARMACOKINETICS, 2018, 57 (07) : 769 - 779
  • [25] Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
    Sreeneeranj Kasichayanula
    Anita Grover
    Maurice G. Emery
    Megan A. Gibbs
    Ransi Somaratne
    Scott M. Wasserman
    John P. Gibbs
    Clinical Pharmacokinetics, 2018, 57 : 769 - 779
  • [26] Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
    Silla, Alessia
    Fogacci, Federica
    Punzo, Angela
    Hrelia, Silvana
    Simoni, Patrizia
    Caliceti, Cristiana
    Cicero, Arrigo F. G.
    ANTIOXIDANTS, 2023, 12 (03)
  • [27] Lipid Therapy PCSK9 highly effective LDL-Reduction and Reduction of cardiovascular Events
    Leithauser, Boris
    AKTUELLE KARDIOLOGIE, 2015, 4 (04) : 216 - 216
  • [28] EFFECT OF PCSK9 INHIBITION WITH EVOLOCUMAB ON THE CONCENTRATION AND COMPOSITION OF LDL SUBFRACTIONS IN HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASE
    Scharnagl, H.
    Kannenkeril, D.
    Stojakovic, T.
    Silbernagel, G.
    Bosch, A.
    Maerz, W.
    Schmieder, R.
    ATHEROSCLEROSIS, 2023, 379 : S71 - S71
  • [29] Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
    Hwang, Hyeon Seok
    Kim, Jin Sug
    Kim, Yang Gyun
    Lee, So-Young
    Ahn, Shin Young
    Lee, Hong Joo
    Lee, Dong-Young
    Lee, Sang Ho
    Moon, Ju Young
    Jeong, Kyung Hwan
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
  • [30] PCSK9 inhibition reduces cardiovascular events in high-risk patients
    Karina Huynh
    Nature Reviews Cardiology, 2017, 14 : 251 - 251
12345